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sponse occurred in 47%. Response was evaluated, before SCT, by
PET scan and Gallium scan in 68 and 147 pts, respectively.
Fifty-one percent of the pts were in complete response (CR) or
unconﬁrmed complete response (CRu), 41% were in partial re-
sponse (PR), and 7% were stable or progressive by CT scan. PET
scan and Gallium scan were positive in 25 of 68 (37%) and 43 of
147 (29%) pts, respectively. Relapses occurred in 44 of 122 (36%)
pts. FI were positive in only 5% of the pts in CR or Cru; in contrast
FI were positive in 54% of pts in PR and in almost all patients with
progressive disease. At 3 years, the cumulative probability of PFS
was 65% for pts with a negative FI versus 22% for pts with a
positive FI (P  .0001). The 3 years OS were 94% and 73% (P 
.001) for pts with positive FI and pts with negative FI, respectively.
The 3 years PFS for pts in PR with negative FI (51%) was similar
to patients in CR (71%) (P  .188) while the 3 PFS for pts in PR
with positive FI was worse (51%) (P  .0001). The 3 years OS was
similar. In a multivariate model, positive FI affected independently
the PFS and the OS. Pre-transplant functional imaging status
predicts outcome in patients with relapsed/refractory HL. Positive
pre-SCT FI confer a poor prognosis, independent of other tradi-
tional pre-salvage prognostic factors. Patients in PR with positive
FI should be offered innovative approaches other than conven-
tional ASCT.
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Introduction: Follicular lymphoma (FL) is regarded as an in-
curable disease and no single treatment has been shown to have a
signiﬁcant impact on overall survival during its relapsing/remitting
phase. Autologous stem cell transplantation has been investigated
with regard to whether such intensive treatment may have a more
signiﬁcant impact on the disease course. Methods: We completed
a retrospective review of a cohort of 139 unpurged autologous stem
cell transplants at the Ottawa Hospital for relapsed, advanced FL
over a period of 10 years with follow-up to the end of 2003. One
hundred seventeen of these transplants were for relapsed non-
transformed FL. The conditioning regimen consisted of Melpha-
lan (140 mg/m2), VP-16 (60 mg/m2), and total body irradiation
(500 or 1200 cGy). A minimum of 2.5 106 CD34 cells/Kg were
collected and infused. Results: The median age of the cohort was
48 years. The median follow-up was 5.6 years. The majority had
FL grade I and 53% were treated in ﬁrst relapse. The estimated
progression-free survival (PFS) was 47% and overall survival (OS)
was 51% at 10 years for all patients. The 5 year PFS of 58% for
patient with non-transformed FL was much better than the 27% 5
year PFS for patients with transformed FL. There was a trend
toward a better 5 year OS for the patients who underwent trans-
plantation for non-transformed FL (71% vs 61%). Relapse oc-
curred in 42 (36%) patients. Within the non-transformed group,
there were a total of 46 deaths (40%), 3 (3%) due to regimen
related toxicity and 9 (7%) due to secondary cancer. The median
survival from diagnosis was 16 years. In a multivariable Cox pro-
portional hazards model, age, a higher TBI dose, sensitivity to
salvage chemotherapy, and lower grade histology were signiﬁcant
prognostic variables. It was also noted that although the OS didn’t
signiﬁcantly differ in those who had 1, 2, or 	2 prior chemother-
apies, their PFS post transplant was signiﬁcantly better than their
respective PFS prior to transplant. Conclusions: We conclude
that unpurged autologous stem cell transplantation following high
dose chemotherapy is a safe and efﬁcacious treatment for multiply
relapsed FL. This treatment may prolong survival when used at
any stage of the disease. At the meeting, a further update of the
data will be presented with follow-up to the end of 2005, extending
the follow-up to 15 years. This will also include an analysis of their
survival after relapse post transplant.
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Conventional chemotherapy is not curative in patients (pts) with
generalized follicular lymphoma (FL), and most of them ultimately
die from the disease, with a median survival of 8 to 10 years. The
addition of rituximab to initial combination chemotherapy (eg,
R-CVP) prolongs duration of response, but the overall results in
high-risk prognostic group are still unsatisfactory. High-dose che-
motherapy and autologous stem cell transplantation (AT) in
younger pts with accumulation of several adverse prognostic fac-
tors can improve their outcome and prolong survival. Between
1997 and 2005, a total of 22 pts (16 women, 6 men) with poor-
prognosis FL grades I and II were intensively treated (antracycline-
based therapy) at our department. Imunochemotherapy with rit-
uximab was administrated in 11 of them. Seven pts achieved
complete remission (CR) and 15 pts partial remission (PR), mostly
with a tumor reduction greater than 75%. After BEAM condition-
ing therapy, median of 8,1  106kg (range, 2,1–20,8  106/kg)
CD34 peripheral blood stem cells were reinfused. At 100 days
following AT, 18 pts were in CR and 4 pts in PR. Three pts in PR
were treated with rituximab and all achieved CR. At the time of
diagnosis, 15 pts had bcl-2/IgH PCR-positive lymphoma cells in
samples from bone marrow (BM). Fourteen pts had no PCR-
detectable lymphoma cells in BM at 100 days after AT, 1 pt cleared
lymphoma cells from BM after rituximab therapy. Five out of 22
pts (23%) relapsed/progressed after a median time of 16 months
from AT and 3 pts died from recurrent lymphoma. Seventeen pts
are still alive in CR with median follow-up of 24 months (range
3–93 months) from AT. Estimated 7 years overall survival and
event free survival rates were 73% and 70%, respectively. Myeloa-
blative chemotherapy and autologous stem cell transplantation in
poor prognosis pts with advanced follicular lymphoma can lead to
long-lasting molecular CR. The standard administration of a front-
line immunochemotherapy with rituximab can further improve the
rate of CR and clear lymphoma cells from BM and peripheral
blood before stem cells collection. Supported by IGA NC-7490
and VVZ MSM 619 895 9205 grants.
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A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL
(autoSCT) FOLLOWED BY REDUCED INTENSITY (RI) ALLOGENEIC
TRANSPLANTATION (AlloSCT) IN CHILDREN AND ADOLESCENTS WITH
RELAPSED HODGKIN’S DISEASE (HD) AND NON-HODGKIN’S LYM-
PHOMA (NHL)
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AlloSCT may be beneﬁcial to patients with relapsed/refractory
HD and NHL by providing a graft versus lymphoma effect.
Carella et al (JCO 2000) and Gutman et al (BMT 2005) demon-
strated the feasibility and success of MA AutoSCT followed by RI
AlloSCT in adults with refractory lymphoma. We investigated MA
AutoSCT followed by RI AlloSCT in children with relapsed/
refractory HD/NHL. Twelve patients entered post reinduction
therapy (3CR2PR post Ifos/Carbo/VP-16, 1PR1CR post Ifos/
Vinorelbine, 1PR post Topotecan/Ifos/Carbo, 1CR post vinorel-
bine/gemcitabine, 1PR post cytarabine/VP-16/MTX, 1PR post
cytarabine/VP-16/L-asp/prednisone, 1CR post carmustine/VP-
16/cyclophosphamide). MA: Cyclophosphamide 1500 mg/m2 
4d, carmustine 100 mg/m2  3d, VP-16 800 mg/m2  3d, 
AutoSCT. CD20 patients received Rituximab (375 mg/m2/
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